E

    Ensysce Biosciences Inc (ENSC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.39
    -0.01 (-1.80%)

    Market Cap: $7.64M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    70%(14/20)
    Avg Surprise
    -90.08%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.19
    Range$-0.19 - $-0.19
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.69-263.2%
    60d ago$-0.49-157.9%
    30d ago$0.09+147.4%
    7d ago$0.04+121.1%
    Current$-0.19
    Revenue Consensus
    $1M
    Range$1M - $1M
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.33
    Range$0.33 - $0.33
    1 analysts
    Revenue Consensus
    $500000
    Range$500000 - $500000
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.33---
    Sep 26EST
    		-$-0.19---
    Jun 26
    Reported Aug 12
    		$-0.20N/A+60.00%Beat+74.7%
    Mar 26
    Reported May 15
    		$-0.52$-0.73+28.77%Beat+62.6%
    Dec 25
    Reported Mar 30
    		$-0.75$-1.26+40.48%Beat+74.1%
    Sep 25
    Reported Nov 14
    		$-1.29$-0.93-38.71%Miss-222.9%
    Jun 25
    Reported Aug 13
    		$-0.79$-1.28+38.28%Beat+76.1%
    Mar 25
    Reported May 13
    		$-1.39$-1.53+9.15%Beat+83.2%
    Dec 24
    Reported Mar 10
    		$-2.90$-1.95-48.72%Miss-111.7%
    Sep 24
    Reported Nov 12
    		$1.05N/A+141.18%Beat+108.0%
    Jun 24
    Reported Aug 14
    		$-3.30$-5.25+37.14%Beat+77.2%
    Mar 24
    Reported May 10
    		$-8.25$-11.25+26.67%Beat+77.3%
    Dec 23
    Reported Mar 15
    		$-1.37$-0.87-57.47%Miss+92.5%
    Sep 23
    Reported Nov 9
    		$-13.05$-15.85+17.67%Beat+97.7%
    Jun 23
    Reported Aug 11
    		$-14.46N/A+81.98%Beat+98.1%
    Mar 23
    Reported May 15
    		$-36.39N/A+58.46%Beat+95.0%
    Dec 22
    Reported Mar 30
    		$-18.24$-28.88+36.84%Beat-102.7%
    Sep 22
    Reported Nov 14
    		$-578.77$-612.00+5.43%Beat-81416.9%
    Jun 22
    Reported Aug 11
    		$-759.02$-468.00-62.18%Miss-1264933.3%
    Mar 22
    Reported May 12
    		$-729.00$-576.00-26.56%Miss-291700.0%
    Dec 21
    Reported Mar 31
    		$-9.00$-0.40-2150.00%Miss-3158.1%
    Sep 21
    Reported Nov 15
    		$-0.71$-0.71+0.00%Beat-2466.7%
    Jun 21
    Reported Aug 16
    		$-0.06N/AN/ABeat-115.0%
    Mar 21
    Reported Jun 7
    		$0.25N/AN/ABeat+586.4%
    Dec 20
    Reported Mar 15
    		$0.29N/AN/ABeat+633.2%
    Sep 20
    Reported Nov 9
    		$0.03N/AN/ABeat-100.0%
    Jun 20
    Reported Aug 7
    		$0.40N/AN/ABeat-99.3%
    Mar 20
    Reported May 7
    		$-0.05N/AN/ABeat-100.0%
    Dec 19
    Reported Mar 10
    		$-0.06N/AN/ABeat+99.9%
    Sep 19
    Reported Nov 7
    		$70.63N/AN/ABeat+267.2%
    Jun 19
    Reported Aug 7
    		$60.45N/AN/ABeat+228.5%
    Mar 19
    Reported May 6
    		$111.77N/AN/ABeat+776.1%
    Dec 18
    Reported Mar 11
    		$-68.52N/AN/ABeat-
    Sep 18
    Reported Nov 7
    		$-42.24N/AN/ABeat-
    Jun 18
    Reported Aug 1
    		$-47.04N/AN/ABeat-
    Mar 18
    Reported May 3
    		$-16.53N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.14EV/EBITDA-0.50x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-280.50%Operating Margin-221.30%
    ROE-1295.00%ROIC1826.94%
    Financial Health
    Debt/Equity-0.25xInterest Coverage-845.64x
    Current Ratio0.70xQuick Ratio0.70x
    Trading Statistics
    Beta0.90Avg Volume41.52M
    52-Week High$2.7552-Week Low$0.23

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.39
    SMA 20$0.40
    SMA 50$0.33
    SMA 200$0.63
    EMA 10$0.39
    EMA 20$0.38
    EMA 50$0.35
    EMA 200$0.78

    MACD

    Line: 0.02Signal: 0.02Hist: -0.00

    ADX

    ADX: 44.0+DI: 40.1-DI: 13.8

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down8.0
    PSAR$0.72

    Bollinger Bands

    Upper Band$0.49
    Lower Band$0.31
    %B Position4515%(Upper)
    Band Width0.44

    RSI (14-Day)

    Neutral
    54.3

    Momentum Oscillators

    Stoch %K40.7
    Stoch %D36.2
    Williams %R-56.8
    ROC (10d)4.3%
    Momentum0.02
    CCI (20d)-24.7
    MFI (14d)58.5

    Volatility Measures

    ATR (14d)$0.06(14.2%)
    StdDev (20d)0.05
    Hist Vol236.2%(High)

    Volume Flow

    VWAP$0.40
    OBV1.3B
    AD Line-524.9M
    CMF (20d)-0.635

    Volume Metrics

    Avg Vol (20d)37.5M
    Vol Ratio0.0x(Low)
    VWMA (20d)$0.48

    Pivot Points

    R3$0.44
    R2$0.43
    R1$0.41
    Pivot Point$0.40
    S1$0.39
    S2$0.37
    S3$0.36

    Advanced Oscillators

    TSI11.68
    Ultimate Osc54.6
    KST323.50

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.16M$960,999$1.88M$493,104$1.37M$1.32M$1.30M$3.42M$181,797$305,722$515,032$435,380
    Cost of RevenueN/A$6,533N/A$2.95M$1.92M$1.89M$3.80M$1.69M$947,229$778,904$2.23M$1.91M
    Gross Profit$1.16M$954,466N/A$-2,461,805$-551,992$1.32M$-2,498,971$1.73M$-765,432$-473,000$-1,717,728$-1,479,590
    Operating Expenses$3.74M$3.56M$2.78M$3.74M$1.75M$1.97M$3.58M$-644,746$1.96M$1.84M$3.16M$2.71M
    R&D$2.47M$3.35M$3.61M$2.95M$1.92M$1.89M$3.80M$1.69M$947,229$778,904$2.23M$1.91M
    SG&A$1.27M$1.18M$1.05M$1.28M$1.20M$1.40M$1.08M$1.08M$1.19M$1.37M$1.44M$1.23M
    Operating Income$-2,576,389$-3,562,230$-2,781,825$-3,741,095$-1,750,515$-1,967,512$-3,576,476$644,746$-1,955,442$-1,842,964$-3,155,685$-2,707,314
    Interest Income$0$0$5,380$6,370$3,160$3,860$10,750$4,060$0$0$0$0
    Interest Expense$320$3,923$5,382$6,369$3,160$3,856$10,753$4,062$27,563$1.25M$344,799$7,649
    Income Before Tax$-2,570,875$-3,556,415$-2,767,969$-3,729,128$-1,733,517$-1,945,573$-3,564,422$661,769$-1,967,793$-3,116,563$-3,504,361$-2,690,806
    Income Tax Expense$0$0$0$0$0$0$74$0$2$-74$360,481$6,414
    Net Income$-2,570,709$-3,556,415$-2,767,648$-3,729,128$-1,733,351$-1,945,573$-3,564,422$661,769$-1,967,793$-3,116,489$-3,503,396$-2,689,571
    EBITDA$-2,582,223$-3,545,959$-2,762,587$-3,722,759$-1,730,357$-1,941,717$-3,553,669$665,832$-1,940,230$-1,868,498$-3,159,562$-2,683,157
    EBITN/A$-3,552,492$-2,769,120$-3,722,759$-3,480,872$-3,909,512$-7,130,145$644,746$-3,895,672$-3,710,964$-6,315,247$-5,390,471
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ENSC

    News

    Ensysce completes enrollment in opioid overdose study By Investing.com

    Ensysce Biosciences has completed enrollment in the final stage of its PF614-MPAR-102 clinical study, which evaluates its MPAR overdose-protection technology for opioid therapy. This milestone advances a Breakthrough Therapy-designated program aimed at reducing the overdose risk associated with prescription opioids. The company is also developing other therapies for pain management and central nervous system conditions.

    Investing.com Australia•8/31/26•
    Bullish

    Ensysce Biosciences raises $21M in initial tranche, meets Nasdaq equity rules, seeks second bid-price grace period

    Ensysce Biosciences has announced that it raised over $21 million in gross proceeds from the initial tranche of a Series C preferred financing, which has allowed the company to meet Nasdaq's equity requirements. The company issued 120,260 shares of Series C preferred stock, totaling approximately $43 million in financing, with the initial closing on August 7 contributing over $21 million. Ensysce Biosciences is now seeking a second 180-day grace period from Nasdaq after asserting it has at least $5 million in equity and eligibility under Rule 5810(c)(3)(A).

    TradingView•8/25/26•
    Somewhat-Bullish

    Ensysce (ENSC) completes private raise with contingent proceeds

    Ensysce Biosciences, Inc. (ENSC) has completed a Rule 506(b) exempt offering, raising $77.2 million through the sale of equity securities, with $38.6 million of this amount subject to contingencies. The first sale occurred on August 5, 2026, and UBS Securities LLC and Cantor Fitzgerald & Co. were involved in sales compensation, along with $200,000 in finders' fees. The filing does not disclose details such as share count or use of proceeds, limiting the economic effect assessment.

    Stock Titan•8/20/26•
    Neutral

    ENSC: Acquisition and financing position CY200 for CRPS advancement, extending cash runway to 2027

    Ensysce Biosciences (ENSC) has announced the acquisition of Cy Biopharma and secured up to $77 million in financing. This move is aimed at advancing CY200, a novel therapy for CRPS, through key clinical milestones. The integration will bring new leadership and extend the company's cash runway into late 2027.

    TradingView•8/18/26•
    Bullish

    Ensysce Biosciences director Gower buys $444,169 in company stock

    Ensysce Biosciences director Bob G. Gower recently purchased $444,169 worth of company common stock through open market transactions between April and August 2026, increasing his direct holdings to over 916,000 shares. These purchases occurred while the stock was trading significantly lower than a year prior, despite analysis suggesting it may be undervalued. The company also received a $5.3 million award for its MPAR technology and is addressing a Nasdaq non-compliance notice regarding its stockholders' equity.

    Investing.com•8/18/26•
    Neutral

    Frequently Asked Questions About ENSC

    Does ENSC pay dividends?
    Ensysce Biosciences Inc (ENSC) does not currently pay a regular dividend.
    What is ENSC's market cap?
    Ensysce Biosciences Inc (ENSC) has a market capitalization of $7.64M with a current stock price of $0.39.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In